Examples of NICE Technology Appraisals in a sentence
NICE Technology Appraisals (TAs) relating to Psoriasis in adults which are published after the approval date of this guideline will be commissioned 90 days (30 days for fast track NICE TAs) from publication in line with the TA recommendations.
No additional charges above cost will be accepted unless specifically identified in 2015/16 national tariff guidelines, explicitly agreed with NHS England and specifically in advance within the contract Drugs as detailed in the current NHS England excluded drug list will be commissioned in line with NHS England commissioning policies and National Institute of Clinical Excellence (NICE) Technology Appraisals (TAs).
With the exception of NICE Technology Appraisals the CCG will not introduce new drugs/technologies in an ad hoc basis through the mechanism of individual case funding.
NICE Technology Appraisals Drugs subject to a NICE Technology Appraisal (TA) require an application to the DTC committee in order to agree a local prescribing protocol for that drug.
B., Wong, R.: Modelling carer health-related quality of life in NICE Technology Appraisals and Highly Specialised Technologies.
It does not and should not over-ride the NICE Technology Appraisals 249, 256 and 275; a clinician may initiate dabigatran, rivaroxaban or apixaban for any patient within the Technology Appraisals’ (TAs) criteria.
Of course, this full DER diffusion scenario would never realistically occur; the purpose of this is therefore not to calculate highly accurate data, but rather to calculate the upper limits for a total capacity potential, and determine a feasible order of magnitude based on this.
The majority of these agents are reasonably expensive but have been granted NICE Technology Appraisals recommending their prescribing in the NHS; updated NICE diabetes guidance is expected to be launched later in 2015 which might reposition some of these therapies earlier in the treatment pathway.
The provider will have a robust process for assessing, implementing and monitoring NICE Technology Appraisals, Clinical Guidance, Interventional Procedures (as appropriate) and other national best practice guidance for example: National Confidential Enquires, National Inquires, National Audits.
The majority of cost pressures from APC decisions for 14-15 (for medicines at the interface) were due to positive NICE Technology Appraisals (namely canagliflozin for diabetes, nalmefene for alcohol misuse and lubiprostone for constipation).